AbbVie Inc. entered into an underwriting agreement on February 24, 2026, to issue and sell senior notes totaling $8 billion in aggregate principal amount. The offering includes seven series of notes with varying maturities and interest rates, ranging from floating rate (Compounded SOFR + 48 bps) to 5.650% fixed rate. The net proceeds from the sale of the notes, after deducting underwriting discounts and estimated offering expenses, are expected to be approximately $7.95 billion. AbbVie intends to use these net proceeds to repay $2.0 billion currently outstanding under its $4.0 billion 364-Day delayed draw term loan facility that matures in May 2026, and for general corporate purposes, which may include the repayment or repurchase of other outstanding debt. The closing of the sale of the notes is expected to occur on March 4, 2026, subject to customary closing conditions.